Opportunity Information: Apply for PA 08 128
Apply for PA 08 128
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Prescription Drug Misuse (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Dec 5, 2008 and posted on Apr 3, 2008.
- Applicants must submit their applications by May 7, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses Small businesses Independent school districts City or township governments County governments Private institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Special district governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Prescription Drug Misuse (R21) funding opportunity (PA 08 128) is an NIH discretionary research grant designed to support exploratory and developmental studies aimed at reducing misuse of prescription medications while still protecting and enabling their appropriate medical use. It is sponsored by the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH) and focuses on therapeutic agents that have legitimate clinical value but also carry abuse liability. The core idea is to fund early-stage, potentially high-impact projects that can clarify what is driving prescription drug misuse and test promising approaches to prevent it, identify it earlier, or reduce its harms without undermining patient access to needed treatments.
The opportunity invites a broad range of research topics and methods. On the population side, it encourages epidemiologic studies that describe the extent and nature of prescription drug misuse and its associated health and social consequences, with attention to specific drug classes and how patterns differ across groups and settings. Applicants are encouraged to identify determinants of misuse, risk and protective factors, and typical trajectories over time (for example, pathways from legitimate prescribing to nonmedical use, escalation, dependence, overdose risk, or transition to other substances). In parallel, the FOA also welcomes basic science work that investigates mechanisms of action at the cellular level and explores biological mechanisms that might be leveraged to reduce abuse potential. This can include identifying targets for medications or strategies that block or lessen reinforcing effects while preserving therapeutic benefit. A third major area is health services and clinical research, including studies that evaluate or develop clinical practices to better identify patients at risk, improve prescribing and monitoring, and design, test, and disseminate prevention and treatment interventions in real-world settings.
This announcement uses the NIH Exploratory/Developmental Research Grant mechanism (R21), which is typically used for early, proof-of-concept, or high-risk/high-reward work that can generate preliminary data or establish feasibility for later, larger-scale research. The FOA is explicitly described as running in parallel with two companion announcements of identical scientific scope: PA 08 127 for the R01 mechanism (generally used for more mature, fully developed projects) and PA 08 129 for the R03 mechanism (often used for small, pilot projects). In other words, NIH is signaling that the topic area is important across project sizes, but this specific listing is for R21-style exploratory efforts.
Funding levels and the number of awards are not fixed in advance because NIH expects substantial variation in what applicants propose. Awards will differ in size and duration depending on the scope, approach, and budget requested, and NIH indicates that the total number of grants and total dollars awarded will ultimately depend on the volume of applications received and their quality, duration, and costs. The announcement lists an award ceiling of $200,000 and notes there is no cost-sharing or matching requirement.
Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Eligible applicants include public and private institutions of higher education, nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities), for-profit organizations (including small businesses), independent school districts, local governments (city/township, county, and special district), state governments, public housing authorities/Indian housing authorities, federally recognized tribal governments, and other tribal organizations. The eligibility section also highlights additional categories such as Alaska Native and Native Hawaiian Serving Institutions, Hispanic Serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), U.S. territories or possessions, regional organizations, faith-based or community-based organizations, eligible federal agencies, and foreign (non-U.S.) entities.
Administratively, the opportunity is cataloged under CFDA 93.242 (Mental Health Research Grants) and 93.279 (Drug Abuse and Addiction Research Programs). It was posted April 3, 2008, with an original and current closing date of May 7, 2011, and an archive date of June 7, 2011, indicating the announcement is no longer active but remains a useful reference for the scope NIH sought under this program. The full text was provided through the NIH Grants Guide, and the listing includes NIH Office of Extramural Research (OER) webmaster contact information for access or linking issues.
Frequently Asked Questions (FAQs): Prescription Drug Misuse (R21) - PA 08-128
1) What is the Prescription Drug Misuse (R21) funding opportunity (PA 08-128)?
PA 08-128 is an NIH discretionary research grant opportunity that uses the Exploratory/Developmental Research Grant mechanism (R21). It is designed to support exploratory and developmental studies aimed at reducing misuse of prescription medications while still protecting and enabling appropriate medical use.
2) Which NIH institutes sponsor this opportunity?
This funding opportunity is sponsored by the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH).
3) What is the main goal of the program?
The core goal is to fund early-stage, potentially high-impact research that clarifies what is driving prescription drug misuse and tests promising approaches to prevent misuse, identify it earlier, or reduce its harms without undermining patient access to needed treatments.
4) What kinds of medications or therapeutic agents are in scope?
The program focuses on therapeutic agents that have legitimate clinical value but also carry abuse liability. The intent is to address misuse and harms while preserving appropriate medical use.
5) What type of research does the R21 mechanism support in this announcement?
The R21 mechanism is typically used for early, proof-of-concept, or high-risk/high-reward projects that can generate preliminary data or establish feasibility for later, larger-scale research.
6) What research topics are encouraged under this FOA?
The FOA invites a broad range of topics and methods, including population/epidemiologic research, basic science research, and health services/clinical research, as long as the work is aimed at understanding and reducing prescription drug misuse while maintaining appropriate access for patients.
7) What does the FOA encourage on the population and epidemiology side?
It encourages epidemiologic studies that describe the extent and nature of prescription drug misuse and associated health and social consequences. The FOA highlights attention to specific drug classes and to differences in patterns across groups and settings.
8) What kinds of misuse determinants or trajectories are specifically mentioned?
Applicants are encouraged to identify determinants of misuse, risk and protective factors, and typical trajectories over time. Examples mentioned include pathways from legitimate prescribing to nonmedical use, escalation, dependence, overdose risk, or transition to other substances.
9) Does the FOA support basic science research?
Yes. The FOA welcomes basic science work that investigates mechanisms of action at the cellular level and explores biological mechanisms that might be leveraged to reduce abuse potential.
10) What kinds of basic science outcomes are envisioned?
Examples described include identifying targets for medications or strategies that block or lessen reinforcing effects while preserving therapeutic benefit.
11) Does the announcement include health services and clinical research?
Yes. A major area of interest is health services and clinical research, including studies that evaluate or develop clinical practices to better identify patients at risk, improve prescribing and monitoring, and design, test, and disseminate prevention and treatment interventions in real-world settings.
12) How does PA 08-128 relate to other NIH announcements?
PA 08-128 is described as running in parallel with two companion announcements of identical scientific scope: PA 08-127 for the R01 mechanism and PA 08-129 for the R03 mechanism. This specific listing is for R21-style exploratory efforts.
13) What is the difference between the R21 opportunity and the companion R01 and R03 opportunities (as described here)?
As described in the listing: R21 is for exploratory/developmental efforts; R01 is generally used for more mature, fully developed projects; and R03 is often used for small, pilot projects. All three are stated to have identical scientific scope in their companion announcements.
14) Is the number of awards or total funding pre-set?
No. Funding levels and the number of awards are not fixed in advance. NIH indicates awards will vary based on project scope, approach, and budget requested, and that total awards and total dollars depend on the volume of applications received and their quality, duration, and costs.
15) What is the award ceiling mentioned in the announcement?
The announcement lists an award ceiling of $200,000.
16) Is cost-sharing or matching required?
No. The announcement states there is no cost-sharing or matching requirement.
17) Who is eligible to apply?
Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Examples listed include public and private institutions of higher education; nonprofit organizations (both 501(c)(3) and non-501(c)(3)); for-profit organizations (including small businesses); independent school districts; local, county, special district, and state governments; public housing authorities/Indian housing authorities; federally recognized tribal governments; and other tribal organizations. The listing also highlights categories such as HBCUs, Hispanic Serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities, U.S. territories or possessions, regional organizations, faith-based or community-based organizations, eligible federal agencies, and foreign (non-U.S.) entities.
18) Are foreign (non-U.S.) entities eligible under this opportunity?
Yes. The eligibility section explicitly includes foreign (non-U.S.) entities.
19) What CFDA program numbers are associated with this opportunity?
This opportunity is cataloged under CFDA 93.242 (Mental Health Research Grants) and 93.279 (Drug Abuse and Addiction Research Programs).
20) When was this opportunity posted and when did it close?
It was posted on April 3, 2008. The original and current closing date listed is May 7, 2011, with an archive date of June 7, 2011.
21) Is this funding opportunity still active?
No. The closing date (May 7, 2011) and archive date (June 7, 2011) indicate the announcement is no longer active, though it remains a useful reference for the scope NIH sought under this program.
22) Where was the full text of the announcement made available?
The full text was provided through the NIH Grants Guide.
23) Who is listed as a contact for access or linking issues?
The listing includes NIH Office of Extramural Research (OER) webmaster contact information for access or linking issues.
Browse more opportunities from the same category: Education Health
Next opportunity: Prescription Drug Misuse (R03)
Previous opportunity: Prescription Drug Misuse (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 08 128
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 08 128) also looked into and applied for these:
| Funding Opportunity |
|---|
| Prescription Drug Misuse (R03) Apply for PA 08 129 Funding Number: PA 08 129 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory/Developmental Grant for Complementary and Alternative Medicine (CAM) Studies of Humans (R21) Apply for PAR 08 135 Funding Number: PAR 08 135 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Correlative Studies with Specimens from Multi Site Trials (R21) Apply for PA 08 133 Funding Number: PA 08 133 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Correlative Studies with Specimens from Multi Site Trials (R01) Apply for PA 08 134 Funding Number: PA 08 134 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R01) Apply for PA 08 143 Funding Number: PA 08 143 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R21) Apply for PA 08 144 Funding Number: PA 08 144 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Science Education Drug Abuse Partnership Award R25 Apply for PAR 08 145 Funding Number: PAR 08 145 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Biomarkers of Infection Associated Cancers (R01) Apply for PA 08 156 Funding Number: PA 08 156 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Biomarkers of Infection Associated Cancers (R21) Apply for PA 08 157 Funding Number: PA 08 157 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Transdisciplinary Research on Fatigue and Fatigability in Aging (R01) Apply for PA 08 161 Funding Number: PA 08 161 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Transdisciplinary Research on Fatigue and Fatigability in Aging (R21) Apply for PA 08 162 Funding Number: PA 08 162 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Stem Cells and Cancer (R21) Apply for PA 08 165 Funding Number: PA 08 165 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Economics of Treatment and Prevention Services for Drug Alcohol Abuse (R03) Apply for PA 08 172 Funding Number: PA 08 172 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Economics of Treatment and Prevention Services for Drug Alcohol Abuse (R01) Apply for PA 08 174 Funding Number: PA 08 174 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Novel Lentiviral Models of HIV Neuropathogenesis (R01) Apply for PAS 08 178 Funding Number: PAS 08 178 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Novel Lentiviral Models of HIV Neuropathogenesis (R21) Apply for PAS 08 179 Funding Number: PAS 08 179 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Exploratory/Developmental Grant for Complementary and Alternative Medicine (CAM) Studies using Cells, Tissues, and Animal Models of Disease (R21) Apply for PA 08 185 Funding Number: PA 08 185 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Medications Development for Polydrug Addiction Treatment (R01) Apply for PAS 08 186 Funding Number: PAS 08 186 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medications Development for Polydrug Addiction Treatment (R21) Apply for PAS 08 187 Funding Number: PAS 08 187 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Integrating Biobehavioral and Sociocultural Research to Prevent HIV Transmission and Infection (R01) Apply for PA 08 188 Funding Number: PA 08 188 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 08 128", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.